Atypical alpha-1 adrenergic receptors on the rat parotid gland acinar cell

J. E. Porter, F. J. Dowd, Peter W. Abel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Subtypes of alpha-1 adrenergic receptors on rat parotid gland acinar cell membranes were characterized using subtype selective alpha adrenergic receptor antagonists. The alpha-1 adrenergic receptor antagonist β-iodo- [125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone (125IBE) had an equilibrium dissociation constant for specific binding sites on these membranes of 0.241 ± 0.03 nM and a total number of specific radioligand binding sites of 41 ± 4 fmol bound/mg of protein. Displacement of 125IBE binding by subtype-selective alpha-1 adrenergic receptor antagonists 2-(2,6- dimethoxyphenoxyethyl)-aminomethyl-1,4-benzodioxane HCl (WB4101) and 5- methylurapidil fit best to biphasic competition curves. The high- and low- affinity inhibition equilibrium dissociation constant for WB4101 were 0.45 ± 0.1 and 27 ± 6 nM, respectively. Similarly, the high- and low-affinity inhibition equilibrium dissociation constants for 5-methylurapidil were 0.16 ± 0.03 and 71 ± 20 nM, respectively. These affinities for 125IBE binding sites suggest the presence of alpha-1A and alpha-1B adrenergic receptor subtypes on acinar cell membranes. The irreversible alpha-1 adrenergic receptor antagonist chloroethylclonidine was used to inactivate alpha-1B adrenergic receptors on acinar cell membranes. After treatment with chloroethylclonidine, saturation binding analysis demonstrated no change in the total number of 125IBE binding sites. In addition, competition curves for WB4101 and 5-methylurapidil again showed two sites of 125IBE displacement, with no change in antagonist affinities in membranes treated with chloroethylclonidine. In contrast, chloroethylclonidine treatment of rat cerebral cortex membranes not only decreased the total number of 125IBE binding sites, but also converted the biphasic competition curve for 5- methylurapidil into a monophasic curve with loss of the low affinity 125IBE binding site. These data reveal an atypical subtype of the alpha-1 adrenergic receptor on the rat parotid gland acinar cell that is different from the alpha-1 adrenergic receptor subtypes previously characterized in the rat cerebral cortex.

Original languageEnglish
Pages (from-to)1062-1067
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume263
Issue number3
StatePublished - 1992

Fingerprint

Adrenergic alpha-1 Receptors
Acinar Cells
Parotid Gland
Adrenergic alpha-1 Receptor Antagonists
Binding Sites
Cell Membrane
Cerebral Cortex
Membranes
Tetralones
Receptors, Adrenergic, alpha
Adrenergic Antagonists
5-methylurapidil
chlorethylclonidine

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Atypical alpha-1 adrenergic receptors on the rat parotid gland acinar cell. / Porter, J. E.; Dowd, F. J.; Abel, Peter W.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 263, No. 3, 1992, p. 1062-1067.

Research output: Contribution to journalArticle

@article{2f4bc260708c42e1b3f4de7b56016b8e,
title = "Atypical alpha-1 adrenergic receptors on the rat parotid gland acinar cell",
abstract = "Subtypes of alpha-1 adrenergic receptors on rat parotid gland acinar cell membranes were characterized using subtype selective alpha adrenergic receptor antagonists. The alpha-1 adrenergic receptor antagonist β-iodo- [125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone (125IBE) had an equilibrium dissociation constant for specific binding sites on these membranes of 0.241 ± 0.03 nM and a total number of specific radioligand binding sites of 41 ± 4 fmol bound/mg of protein. Displacement of 125IBE binding by subtype-selective alpha-1 adrenergic receptor antagonists 2-(2,6- dimethoxyphenoxyethyl)-aminomethyl-1,4-benzodioxane HCl (WB4101) and 5- methylurapidil fit best to biphasic competition curves. The high- and low- affinity inhibition equilibrium dissociation constant for WB4101 were 0.45 ± 0.1 and 27 ± 6 nM, respectively. Similarly, the high- and low-affinity inhibition equilibrium dissociation constants for 5-methylurapidil were 0.16 ± 0.03 and 71 ± 20 nM, respectively. These affinities for 125IBE binding sites suggest the presence of alpha-1A and alpha-1B adrenergic receptor subtypes on acinar cell membranes. The irreversible alpha-1 adrenergic receptor antagonist chloroethylclonidine was used to inactivate alpha-1B adrenergic receptors on acinar cell membranes. After treatment with chloroethylclonidine, saturation binding analysis demonstrated no change in the total number of 125IBE binding sites. In addition, competition curves for WB4101 and 5-methylurapidil again showed two sites of 125IBE displacement, with no change in antagonist affinities in membranes treated with chloroethylclonidine. In contrast, chloroethylclonidine treatment of rat cerebral cortex membranes not only decreased the total number of 125IBE binding sites, but also converted the biphasic competition curve for 5- methylurapidil into a monophasic curve with loss of the low affinity 125IBE binding site. These data reveal an atypical subtype of the alpha-1 adrenergic receptor on the rat parotid gland acinar cell that is different from the alpha-1 adrenergic receptor subtypes previously characterized in the rat cerebral cortex.",
author = "Porter, {J. E.} and Dowd, {F. J.} and Abel, {Peter W.}",
year = "1992",
language = "English",
volume = "263",
pages = "1062--1067",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Atypical alpha-1 adrenergic receptors on the rat parotid gland acinar cell

AU - Porter, J. E.

AU - Dowd, F. J.

AU - Abel, Peter W.

PY - 1992

Y1 - 1992

N2 - Subtypes of alpha-1 adrenergic receptors on rat parotid gland acinar cell membranes were characterized using subtype selective alpha adrenergic receptor antagonists. The alpha-1 adrenergic receptor antagonist β-iodo- [125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone (125IBE) had an equilibrium dissociation constant for specific binding sites on these membranes of 0.241 ± 0.03 nM and a total number of specific radioligand binding sites of 41 ± 4 fmol bound/mg of protein. Displacement of 125IBE binding by subtype-selective alpha-1 adrenergic receptor antagonists 2-(2,6- dimethoxyphenoxyethyl)-aminomethyl-1,4-benzodioxane HCl (WB4101) and 5- methylurapidil fit best to biphasic competition curves. The high- and low- affinity inhibition equilibrium dissociation constant for WB4101 were 0.45 ± 0.1 and 27 ± 6 nM, respectively. Similarly, the high- and low-affinity inhibition equilibrium dissociation constants for 5-methylurapidil were 0.16 ± 0.03 and 71 ± 20 nM, respectively. These affinities for 125IBE binding sites suggest the presence of alpha-1A and alpha-1B adrenergic receptor subtypes on acinar cell membranes. The irreversible alpha-1 adrenergic receptor antagonist chloroethylclonidine was used to inactivate alpha-1B adrenergic receptors on acinar cell membranes. After treatment with chloroethylclonidine, saturation binding analysis demonstrated no change in the total number of 125IBE binding sites. In addition, competition curves for WB4101 and 5-methylurapidil again showed two sites of 125IBE displacement, with no change in antagonist affinities in membranes treated with chloroethylclonidine. In contrast, chloroethylclonidine treatment of rat cerebral cortex membranes not only decreased the total number of 125IBE binding sites, but also converted the biphasic competition curve for 5- methylurapidil into a monophasic curve with loss of the low affinity 125IBE binding site. These data reveal an atypical subtype of the alpha-1 adrenergic receptor on the rat parotid gland acinar cell that is different from the alpha-1 adrenergic receptor subtypes previously characterized in the rat cerebral cortex.

AB - Subtypes of alpha-1 adrenergic receptors on rat parotid gland acinar cell membranes were characterized using subtype selective alpha adrenergic receptor antagonists. The alpha-1 adrenergic receptor antagonist β-iodo- [125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone (125IBE) had an equilibrium dissociation constant for specific binding sites on these membranes of 0.241 ± 0.03 nM and a total number of specific radioligand binding sites of 41 ± 4 fmol bound/mg of protein. Displacement of 125IBE binding by subtype-selective alpha-1 adrenergic receptor antagonists 2-(2,6- dimethoxyphenoxyethyl)-aminomethyl-1,4-benzodioxane HCl (WB4101) and 5- methylurapidil fit best to biphasic competition curves. The high- and low- affinity inhibition equilibrium dissociation constant for WB4101 were 0.45 ± 0.1 and 27 ± 6 nM, respectively. Similarly, the high- and low-affinity inhibition equilibrium dissociation constants for 5-methylurapidil were 0.16 ± 0.03 and 71 ± 20 nM, respectively. These affinities for 125IBE binding sites suggest the presence of alpha-1A and alpha-1B adrenergic receptor subtypes on acinar cell membranes. The irreversible alpha-1 adrenergic receptor antagonist chloroethylclonidine was used to inactivate alpha-1B adrenergic receptors on acinar cell membranes. After treatment with chloroethylclonidine, saturation binding analysis demonstrated no change in the total number of 125IBE binding sites. In addition, competition curves for WB4101 and 5-methylurapidil again showed two sites of 125IBE displacement, with no change in antagonist affinities in membranes treated with chloroethylclonidine. In contrast, chloroethylclonidine treatment of rat cerebral cortex membranes not only decreased the total number of 125IBE binding sites, but also converted the biphasic competition curve for 5- methylurapidil into a monophasic curve with loss of the low affinity 125IBE binding site. These data reveal an atypical subtype of the alpha-1 adrenergic receptor on the rat parotid gland acinar cell that is different from the alpha-1 adrenergic receptor subtypes previously characterized in the rat cerebral cortex.

UR - http://www.scopus.com/inward/record.url?scp=0027000862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027000862&partnerID=8YFLogxK

M3 - Article

C2 - 1335054

AN - SCOPUS:0027000862

VL - 263

SP - 1062

EP - 1067

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -